In a bid to expand its presence in solid tumours, Seagen has entered into a licensing agreement with Lava Therapeutics in a deal worth up to US$700 M. Seagen will be granted access to LAVA-1223, a bispecific gamma deltaT-cell engager drug candidate for epidermal growth factor receptor (EGFR)-expressing solid tumours, which is developed using Lava’s Gammabody™ technology platform. The deal will help Seagen to diversify its portfolio beyond antibody-drug conjugate technology in the treatment of cancer, an area it has historically been focused on.